Citation, commencement and extent

1. —(1) These Regulations may be cited as the Misuse of Drugs (Amendment No. 3) (England, Wales and Scotland) Regulations 2014 and come into force on 7th January 2015.

(2) These Regulations extend to England and Wales and Scotland.

Amendment of the Misuse of Drugs Regulations 2001

2.The Misuse of Drugs Regulations 2001( 2 ) are amended as follows.

3. In paragraph 1(a) of Schedule 1 (which specifies controlled drugs subject to the requirements of regulations 14, 15, 16, 18, 19, 20, 23, 26 and 27)—

(a) after “Tenocyclidine” insert—

“ (6a R ,9 R )-4-acetyl- N , N -diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3- fg ]quinoline-9-carboxamide (ALD-52) ” ;

(b) after “4-bromo-2,5-dimethoxy- a -methylphenethylamine” insert—

“ 3,4-dichloro- N -[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921)

(6a R, 9 R )- N,N- diethyl-7-allyl-4,6,6a,7,8,9-hexahydroindolo[4,3- fg ]quinoline-9-carboxamide (AL-LAD)

(6a R, 9 R ) -N,N- diethyl-7-ethyl-4,6,6a,7,8,9-hexahydroindolo[4,3 -fg ]quinoline-9-carboxamide (ETH-LAD)

(6a R, 9 R )- N,N- diethyl-7-propyl-4,6,6a,7,8,9-hexahydroindolo[4,3- fg ]quinoline-9-carboxamide (PRO-LAD) ” ;

(c) after “2-((Dimethylamino)methyl)-1-(3-hydroxyphenyl)cyclohexanol” insert—

“ 2,4-dimethylazetidinyl{(6a R, 9 R )-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3- fg ]quinolin-9-yl}methanone (LSZ) ” .

4. For paragraph 1(b) of Schedule 1, substitute—

“ (b) any compound (not being a compound for the time being specified in sub-paragraph (a) above) structurally derived from tryptamine or from a ring-hydroxy tryptamine by modification in any of the following ways, that is to say—

(i) by substitution at the nitrogen atom of the sidechain to any extent with alkyl or alkenyl substituents, or by inclusion of the nitrogen atom of the side chain (and no other atoms of the side chain) in a cyclic structure;

(ii) by substitution at the carbon atom adjacent to the nitrogen atom of the side chain with alkyl or alkenyl substituents;

(iii) by substitution in the 6-membered ring to any extent with alkyl, alkoxy, haloalkyl, thioalkyl, alkylenedioxy, or halide substituents;

(iv) by substitution at the 2-position of the tryptamine ring system with an alkyl substituent; ” .

5. In Schedule 2 (which specifies controlled drugs subject to the requirements of regulations 14, 15, 16, 18, 19, 20, 21, 23, 26 and 27) after “Hydropmorphone” insert—

“ 4-Hydroxy-n-butyric acid ” .

6. In paragraph 1 of Part 1 of Schedule 4 (which specifies controlled drugs subject to the requirements of regulations 22, 23, 26 and 27) omit “4-Hydroxy-n-butyric acid”.